An early economic evaluation of active surveillance for low-risk ductal carcinoma in situ

被引:0
|
作者
Byng, Danalyn [1 ,2 ]
Schaapveld, Michael [1 ]
Lips, Esther H. [3 ]
van Duijnhoven, Frederieke H. [4 ]
Wesseling, Jelle [3 ,5 ]
van Harten, Wim H. [1 ,2 ]
Retel, Valesca P. [1 ,2 ]
机构
[1] Netherlands Canc Inst Antoni van Leeuwenhoek Hosp, Div Psychosocial Res & Epidemiol, NL-1066 CX Amsterdam, Netherlands
[2] Erasmus Univ, Erasmus Sch Hlth Policy & Management, NL-3062 PA Rotterdam, Netherlands
[3] Netherlands Canc Inst Antoni van Leeuwenhoek Hosp, Div Mol Pathol, NL-1066 CX Amsterdam, Netherlands
[4] Netherlands Canc Inst Antoni van Leeuwenhoek Hosp, Div Surg Oncol, NL-1066 CX Amsterdam, Netherlands
[5] Leiden Univ Med Ctr, Dept Pathol, NL-2333 ZA Leiden, Netherlands
关键词
active surveillance; biomarkers; cost-effectiveness; ductal carcinoma in situ; early economic evaluation; CLINICAL-PRACTICE GUIDELINES; COST-EFFECTIVENESS ANALYSIS; INVASIVE BREAST-CANCER; CONTINUOUS-TIME; MARKOV-MODELS; PHASE-III; FOLLOW-UP; RADIOTHERAPY; RECURRENCE; SURGERY;
D O I
10.1080/14796694.2024.2421152
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: Perform early economic evaluation comparing active surveillance (AS) to surgery for women with low-risk ductal carcinoma in situ, a precursor of invasive breast cancer. Materials & methods: A 10-year incremental costs (Euro) and quality-adjusted life years (QALYs) were compared between a simulated cohort of women undergoing breast conserving surgery +/- radiotherapy, and a cohort with a low-risk subgroup undergoing AS using a semi-Markov model. Scenario and headroom analyses evaluated a better-performing biomarker to select low-risk women for AS. Results: AS resulted in lower costs and survival, but higher QALYs (0.40). Scenario analyses maintained survival outcomes and maximized QALYs. Conclusion: AS for low-risk ductal carcinoma in situ is cost-effective, but a better-performing biomarker to select low-risk women can maximize quality-adjusted outcomes.
引用
收藏
页码:3451 / 3462
页数:12
相关论文
共 50 条
  • [1] An early cost-effectiveness analysis of active surveillance for low-risk ductal carcinoma in situ
    Byng, D.
    Schaapveld, M.
    Lips, E.
    van Duijnhoven, F.
    Wesseling, J.
    van Harten, W.
    Retel, V.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 20 - 20
  • [2] Oncological safety of active surveillance for low-risk ductal carcinoma in situ — a systematic review and meta-analysis
    Matthew G. Davey
    Aoife J. Lowery
    Michael J. Kerin
    Irish Journal of Medical Science (1971 -), 2023, 192 : 1595 - 1600
  • [3] Oncological safety of active surveillance for low-risk ductal carcinoma in situ - a systematic review and meta-analysis
    Davey, Matthew G.
    Lowery, Aoife J.
    Kerin, Michael J.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2023, 192 (04) : 1595 - 1600
  • [4] Oncological Safety of Active Surveillance for Low-Risk Ductal Carcinoma In-Situ - A Systematic Review and Meta-Analysis
    Nohilly, Aoife
    Davey, Matthew G.
    Lowery, Aoife J.
    Kerin, Michael J.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2022, 191 : S217 - S217
  • [5] Active Surveillance for Low-risk Papillary Thyroid Carcinoma
    Yang, Shijie
    Tan, Meijuan
    Xu, Xiequn
    JAMA ONCOLOGY, 2023, 9 (05) : 722 - 722
  • [6] Outcomes of Active Surveillance for Ductal Carcinoma in Situ: A Computational Risk Analysis
    Ryser, Marc D.
    Worni, Mathias
    Turner, Elizabeth L.
    Marks, Jeffrey R.
    Durrett, Rick
    Hwang, E. Shelley
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (05):
  • [7] De-Escalating Breast or Low-Risk Ductal Carcinoma in Situ
    Hwang, E. Shelley
    Thompson, Alastair M.
    Wesseling, Jelle
    JAMA ONCOLOGY, 2020, 6 (07) : 1117 - 1118
  • [8] Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ
    Partridge, Ann H.
    Hyslop, Terry
    Rosenberg, Shoshana M.
    Bennett, Antonia V.
    Drier, Sarah
    Jonsson, Mattias
    Shimada, Ayako
    Li, Yutong
    Li, Yan
    Lynch, Thomas
    Frank, Elizabeth
    Collyar, Deborah
    Basila, Desiree
    Pinto, Donna
    Weiss, Anna
    Wolf, Anna
    Norris, Kelsey
    Witten, Meredith
    Boisvert, Marc
    Giuliano, Armando
    Larson, Kelsey E.
    Yost, Kathleen
    Mcauliffe, Priscilla F.
    Krie, Amy
    Tamirisa, Nina
    Darai, Sonja
    Carey, Lisa
    Thompson, Alastair
    Hwang, E. Shelley
    COMET Study Consortium
    JAMA ONCOLOGY, 2024,
  • [9] Ductal carcinoma in situ: treatment or active surveillance?
    Kuerer, Henry M.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (07) : 777 - 785
  • [10] Not all ductal carcinoma in situ is created equal: can we avoid surgery for low-risk ductal carcinoma in situ?
    Lippey, Jocelyn
    Spillane, Andrew
    Saunders, Christobel
    ANZ JOURNAL OF SURGERY, 2016, 86 (11) : 859 - 860